Notice: Expedited Review of Health Product Submissions and Applications to address COVID-19
Description
COVID-19 is a new disease not previously identified in humans. Currently there is no vaccine or therapeutic product for COVID-19 that is authorized to treat or prevent the disease. The outbreak of COVID-19 has resulted in a global review of therapies that could be used to treat or prevent the infection. In an effort to facilitate earlier access to a vaccine, or therapeutic product for COVID-19, the Department will expedite the review of any COVID-19 related health product submissions and applications. Doing this will ensure timely access to novel therapies without compromising the safety, efficacy and quality of products.
Resources
| Name |
Format |
Description |
Link |
| Notice: Expedited Review of Health Product Submissions and Applications to address COVID-19 |
HTML |
|
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-expediated-review-health-products-covid-19.html |
| Notice: Expedited Review of Health Product Submissions and Applications to address COVID-19 |
HTML |
|
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/annonces/avis-examen-accelere-presentations-produits-sante-covid-19.html |